METAL OXIDES NANOPARTICLES CONJUGATED WITH NAPHTHALENE DERIVATIVES AS CONTRAST AGENTS FOR THE DETECTION OF BETA AMYLOID PLAQUES BY MAGNETIC RESONANCE IMAGES
申请人:Centro De Neurociencias De Cuba
公开号:EP3878475A1
公开(公告)日:2021-09-15
This invention is related to Chemistry and Physics applied to the field of Medicine and refers to the use of compounds with magnetic properties, which belong to the category of metal oxide nanoparticles, coated and conveniently functionalized, which are conjugated with naphthalene compounds related to agglomerates and β-amyloid plaques present in neurodegenerative diseases. These new nanoparticles (NPs) are used for the non-invasive detection of agglomerates and amyloid plaques using the Magnetic Resonance Imaging (MRI) technique. The nanoparticles described here cross the blood-brain barrier (BBB), without the use of any membrane-disrupting agent. Likewise, they bind with high affinity and specificity to the agglomerates and β-amytoid plaques, and are used as contrast agents in MRI for the early detection of Alzheimer's disease (AD).
The new nanoparticles, coated, functionalized and conjugated with the naphthalene derivatives, have general Formula I;
wherein:
R1: is an organic coating to the metal oxide core, of polymeric type, catechol derivatives and trialkoxyalkylaminosilane;
R2: -NHCO-alkylenyl-C(O)NH-alkylenyl-R3;
R3: -COO-, -CO-, -NH, -O-, -S-, -NH-alkylenyl-NH-, -NR4-CSS-;
R4: -H, -CH3, -CH2-CH3, -CH2CH2CH3, and
MxOy: iron oxide (Fe3O4/γFe2O3), gadolinium oxide(III), manganese oxide(II) and copper(II) oxide;
wherein the conjugated, functionalized and coated magnetic nanoparticle is capable of, when it is administered to a mammal, crossing the blood-brain barrier and specifically binding to the agglomerates and amyloid plaques present in brain tissue;
wherein with this nanoparticle bound to the agglomerates and β-amyloid plaques in the brain tissue, hypo- or hyper-intense signals are observed in the region of interest through MRI.
The compounds of Formula I are capable of acting as positive (T1) and / or negative (T2) contrast agents for MRI for the early and non-invasive diagnosis of AD, through a hypo- or hyper-intense signal of the β-amytoid agglomerates or Aβ plaques.
In the NPs of Formula I, the metallic oxide magnetic core is coated with a functionalized polymeric layer that allows conjugation to naphthalene compounds, the preparation of which has been previously described in CU 2010/0204, EP 2 436 666 A20, P58243ZA00, US 9,764,047, CA 2789869C, PI 2012003534.
The covalent and stable bond between the two chemical units form, in the NPs, a carbon chain with a singular structure, which surprisingly facilitates the NPs passage through the BBB, without the use of a disrupting agent, what are not described in the current state-of-the-art.
These NPs unexpectedly enhance the affinity and selectivity properties of the naphthalene derivatives towards the Aβ agglomerates and β-plaques, they are stable molecules and do not show toxicity. We are not aware that the compounds presented in this invention have been previously reported.
本发明与应用于医学领域的化学和物理学有关,是指使用具有磁性的化合物,这些化合物属于金属氧化物纳米粒子的范畴,经过涂层和方便的功能化处理,与神经退行性疾病中存在的团聚体和β-淀粉样蛋白斑块相关的萘化合物共轭。这些新型纳米粒子(NPs)可用于利用磁共振成像(MRI)技术对团块和淀粉样蛋白斑块进行无创检测。这里描述的纳米粒子可穿过血脑屏障(BBB),无需使用任何膜破坏剂。同样,它们还能以高亲和力和特异性与团块和β-类淀粉样蛋白斑块结合,可用作核磁共振成像中的造影剂,用于早期检测阿尔茨海默病(AD)。
新的纳米粒子具有萘衍生物的涂层、功能化和共轭,其通式为 I;
其中
R1:是金属氧化物核心的有机涂层,聚合物类型,邻苯二酚衍生物和三烷氧基烷基氨基硅烷;
R2:-NHCO-烯基-C(O)NH-烯基-R3;
R3:-COO-、-CO-、-NH、-O-、-S-、-NH-烯基-NH-、-NR4-CSS-;
R4:-H、-CH3、-CH2-CH3、-CH2CH2CH3,以及
MxOy:氧化铁(Fe3O4/γFe2O3)、氧化钆(III)、氧化锰(II)和氧化铜(II);
其中,共轭、功能化和涂层的磁性纳米粒子在给哺乳动物用药时,能够穿过血脑屏障,并与脑组织中的团聚体和淀粉样斑块特异性结合;
其中,当该纳米粒子与脑组织中的团聚体和β-淀粉样蛋白斑块结合后,通过核磁共振成像可在相关区域观察到低强或高强信号。
式 I 的化合物能够作为磁共振成像的阳性(T1)和/或阴性(T2)造影剂,通过 β 淀粉样蛋白团块或 Aβ 斑块的低强或高强信号,进行 AD 的早期无创诊断。
在式 I 的 NPs 中,金属氧化物磁芯上涂有一层可与萘化合物共轭的官能化聚合物层,其制备方法已在 CU 2010/0204、EP 2 436 666 A20、P58243ZA00、US 9,764,047、CA 2789869C、PI 2012003534 中进行过描述。
两个化学单元之间的共价稳定键在 NPs 中形成了一个具有奇异结构的碳链,这出乎意料地促进了 NPs 通过 BBB,而无需使用干扰剂,这在目前的先进技术中还没有描述。
这些 NPs 意外地增强了萘衍生物对 Aβ 团聚体和β斑块的亲和性和选择性,它们是稳定的分子,没有毒性。我们不知道本发明中提出的化合物以前是否被报道过。